At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NERV Minerva Neurosciences
Post-Market Trading 01-08 19:59:30 EST
2.23
-0.12
-5.10%
盘后2.24
+0.01+0.44%
16:00 EST
High2.29
Low2.21
Vol8.02K
Open2.29
D1 Closing2.35
Amplitude3.40%
Mkt Cap15.60M
Tradable Cap12.13M
Total Shares6.99M
T/O18.04K
T/O Rate0.15%
Tradable Shares5.44M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Minerva Neurosciences Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Minerva Neurosciences Q2 2024 GAAP EPS $(1.09) Misses $(0.73) Estimate, Cash, Cash Equivalents And Restricted Cash At June 30, 2024 Were Approximately $31M
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.